{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["PEXG"]],"indication":"resectable pancreatic adenocarcinoma","name":"PACT-15","nct_id":"NCT01150630","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pact-15-nct01150630. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PACT-15","arms":[{"description":"cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 6 months","label":"adjuvant PEXG","type":"EXPERIMENTAL"},{"description":"cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 3 months before surgery and 3 months after surgery","label":"perioperative PEXG","type":"EXPERIMENTAL"},{"description":"Adjuvant Gemcitabine at 1000 mg/mq for 3 weeks every 4 weeks for 6 months","label":"Adjuvant Gemcitabine","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2017-08","type":"ACTUAL"},"conditions":["Pancreatic Cancer"],"enrollment":{"count":98,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"capecitabine","otherNames":["XELODA"],"type":"DRUG"},{"name":"cisplatin","otherNames":["cisplatino TEVA"],"type":"DRUG"},{"name":"epirubicin","otherNames":["farmorubicina"],"type":"DRUG"},{"name":"gemcitabine","otherNames":["GEMZAR"],"type":"DRUG"}],"last_update":"2017-09-01","lead_sponsor":"IRCCS San Raffaele","official_title":"Randomized Phase II-III Trial of Peri- or Post-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2017-04","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-free survival at 1 year (phase II)","timeFrame":"every 3 months"}],"references":[{"citation":"Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423. doi: 10.1016/S2468-1253(18)30081-5. Epub 2018 Apr 4.","pmid":"29625841","type":"DERIVED"}],"start_date":{"date":"2010-05"},"study_type":"INTERVENTIONAL","title":"Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT01150630"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pact-15-nct01150630"}